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Abstract
Prostate cancer accounts for one-third of new cases of cancer per year, and is now the most frequent type 
of cancer in men. Recent data suggest that diabetic patients who take metformin, the drug most commonly 
used in type 2 diabetes, have a lower incidence of certain cancers, such as prostate cancer. Numerous stu-
dies have examined the antineoplastic potential of metformin, although its mechanisms are not yet fully 
understood and the data obtained are ambiguous. This review summarizes the information regarding 
the effects of metformin on prostate cancer cells, highlighting some of the mechanisms of action through 
metformin could play an important role in the management of prostate cancer in the future, both in mo-
notherapy and combined therapy. At this stage, however, it is still necessary to carry out more effective/
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1. Introduction
Prostate cancer (PCa) is the most frequent cancer 
among men and the second leading cause of onco-
logical death (1). Due to its high prevalence, in ad-
dition to new molecules, some drugs indicated for 
other pathologies are being used to treat it. 
Metformin is a type of drug commonly used in 
type 2 diabetes mellitus (T2DM). Although its me-
chanisms are not yet fully understood, its antineo-
-
and evolution.
However, there is disagreement between the di-
fferent sources of information in relation to the me-
chanisms and effects of metformin on PCa.
The aim of this article is to present the diffe-
rent aspects of PCa evolution and treatment in 
effects. This article is focused on the application and 
observable effects of metformin in clinical practice, 
as well as on the different chemical and metabolic 
pathways that metformin is believed to affect.
2. Metformin action mechanisms
In relation to its effect on PCa, two mechanisms of 
action are described (Fig. 1). One of them has a di-
rect effect on tumor cells (by inhibiting the electron 
transport chain) (2), and the other is indirect, redu-
cing levels of insulin and other growth factors (such 
as androgenic receptors, which are fundamental in 
PCa). In addition, metformin blocks the mechanis-
ms through which tumor cells obtain energy: he-
patic gluconeogenesis and glycolysis (the latter if 
combined with 2-deoxyglucose) (3). Although the 
indirect action is interesting considering the or-
-
ms are not fully established. Thus, we will focus on 
developing the direct mechanism of action on tu-
mor cells.
Metformin directly inhibits the mitochondrial res-
piratory chain. This reduces the adenosine triphos-
phate (ATP) levels and increases the AMP/ATP 
ratio, which involves the activation of adenosine 
monophosphate kinase (AMPK) and reduces glu-
cose production (4). Under these stressful condi-
tions, liver kinase B1 (LKB1), known for its tumor 
suppressant role, will activate AMPK and reduce 
-
hibiting mTOR activates the Pl3k/Akt/mTOR sig-
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naling pathway, associated with abnormal cell pro-
liferation, apoptosis inhibition, and carcinogenesis. 
On the other hand, activating the AMPK pathway 
increases the production of the transcription factor 
Forkhead box O3 (FOXO3). The inactivation of this 
gene is involved in the progression of PCa, making 
its activation through metformin a therapeutic op-
tion (6).
2.2. Mechanisms independent of AMPK
Activation of AMPK is the main antineoplastic me-
chanism of metformin, but other pathways have 
been described. For example, Sarah et al. stated that 
Redd1 and cyclin D1 mediate the antiproliferative 
effects of metformin on PCa cells (7). This effect 
is also induced by metformin when the LKB1 pa-
thway is active reducing its messenger RNA, and 
decreasing c-MYC levels (8,9,10). This action is fun-
damental, since androgens induce an increased re-
gulation of insulin growth factor type 1 receptors 
(IGF-1R) and insulin receptors (IR), which are alre-
ady overexpressed in PCa tumor cells. When these 
receptors are activated, the mTOR pathway stimu-
lates cell proliferation and invasion. Finally, other 
research highlights that metformin also blocks the 
COX2/PGE2/STAT2/epithelium-mesenchymal 
transition (EMT) axis and the Fox M1 factor, both of 
which play a central role in cell cycle regulation, an-
giogenesis, invasion, metastasis, and EMT; the last 
of which will also be reduced by the modulation of 
microRNAs (11,12).
Therefore, metformin acts on a wide variety of 
molecular targets and thousands of transduction 
-
cant effects on benign cells, which suggests that its 
(8). The antineoplastic activity of metformin could 
explain the decrease in the incidence of different 
types of cancer (colon, breast or pancreas), in vivo 
and in vitro, when metformin is used as a treatment 
(13). A decrease in tumor proliferation was deter-
mined in vitro in mice, however, the doses used in 
this type of studies are between 100 and 300 times 
higher than those used in standard antidiabetic 
treatments (14). On the other hand, another study 
showed a decrease in Ki 67 in 30% of cancer patients 
(both diabetic and non-diabetic) before undergoing 
PSA (PCa marker). Nevertheless, the methodology 
-
though metformin has an effect on osteoblasts and 
tumor stem cells in vitro, its effects on bone metas-
tases have not been demonstrated (10).
3. Effects of metformin in various 
3.1. Diabetic and obese patients
Diabetes is a risk factor for cancer (16). However, a 
decrease in cancer occurrence has been observed in 
diabetic patients taking metformin, as compared to 
those not taking it (7.3% vs. 11.6%). This effect has 
not been observed with other antidiabetic drugs, 
such as sulfonylureas (17). Although the use of me-
tformin has also been associated with a lower mor-
tality rate associated with the use of metformin has 
also been reported; however, discrepancies have 
been documented in the results, probably due to 
(18). In contrast, other research denies the protecti-
ve role of metformin in PCa (19). Similarly, several 
studies have shown that metformin, used as a treat-
ment in the early and late stages of cancer, has no 
effect (20-23). In response to this conclusion, some 
researchers highlight the lack of studies involving 
Contrary to the works previously mentioned, 
some authors have suggested that type 2 diabetes 
mellitus (T2DM) and obesity could have a certain 
even greater than that of metformin (which, in con-
trast, would inhibit this effect). These pathologies 
reduce the levels of androgens (testosterone and 
dihydrotestosterone) and of the genetic factors that 
stimulate the initial growth of tumor cells (24). In 
addition, they noted that the use of metformin for 
the prevention or treatment of PCa among the gene-
the lack of conclusive data, metformin is the drug 
are many confounding factors because studies are 
retrospective and there are few works on non-dia-
betics. Thus, it is impossible to determine whether it 
is really diabetes control, and not metformin itself, 
that reduces the risk of developing cancer. Similar-
ly, more extensive research is needed in order to as-
sess the long-term effects of this drug.
Androgen deprivation therapy (ADT), usually per-
formed with the administration of gonadotrophin-re-
leasing hormone (GnRH), is the usual treatment for 
locally advanced, recurrent or metastatic PCa. ADT 
induces apoptosis of 2-3% of tumor cells. However, 
it also activates other mechanisms such as autopha-
gy (due to increased activity of AMPK), necrosis, or 
quiescence. Quiescent cells are still viable and can re-
turn to the cell cycle (Fig. 2). As a result, although ini-
tially there is a high response to ADT, these cancers 
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clinical studies suggest that ADT induces changes in 
tumor cells, making them more susceptible to the 
effect of other synergistic treatments, such as doce-
taxel (improves survival). For this reason, several 
studies explore combined therapy with metformin, 
-
3.3. Use of metformin to treat the adverse effects 
of ADT
ADT can cause a range of adverse side effects (Ta-
libido and impotence, bone-related complications 
(osteoporosis), anemia, and cognitive dysfunction. 
Notably, some metabolic and cardiovascular effects 
(obesity, dyslipidemia, increase in resistance to in-
sulin, and diabetes) could potentially be avoided by 
taking metformin (28, 29). In a retrospective study 
of 87,344 elderly patients, Richard KA et al. demons-
trated that metformin combined with ADT impro-
ved the overall survival rate in patients with type 2 
diabetes, reduced the risk of skeletal complications 
and the need for radiotherapy or surgery due to 
these conditions (30). Conversely, Nobes et al. (34) 
found that a change in lifestyle (diet and exercise) 
in non-diabetic patients, combined with metformin, 
helped to reduce weight, body mass index, systolic 
blood pressure, and the risk of contracting diabetes 
(combined with ADT and compared to the control 
group). However, in that study, no differences were 
found in markers of insulin resistance. The study 
did not attempt to show the increase in overall sur-
vival rate, and it is not clear whether these changes 
were the result of using metformin or the changes 
in lifestyle (31). The available evidence points to 
the combination of ADT with metformin being a 
potentially effective option for improving the sur-
vival rate of patients, either through its effects on 
of ADT.
3.4. Patients in ADT with hormone-resistant 
tumors
Between 10-20% of patients with PCa become re-
sistant to ADT. This is called castration-resistant 
prostate cancer (CRPC) (32). This type of cancer 
is linked to genetic disorders such as mutation or 
replication of the androgen receptor (AR) gene, 
or overexpression of the genes responsible for the 
conversion of androgens into dihydrotestosterone 
(33). In these cases, administering metformin is re-
commended due to its safe pharmacological pro-
(PI3K/Akt inhibitors and antiandrogens), and its 
therapeutic action against the side effects of these 
treatments (nausea, vomiting, diarrhea, and hyper-
glycemia) (34). Although both metformin and the 
combination of antiandrogens and PI3K inhibitors 
each cause diarrhea, the interaction of these drugs 
does not increase the occurrence of diarrhea compa-
Given the observed disruption to the PI3K/Akt 
pathway (by 42% in localized PCa cases and by 
100% in advanced stages) (36), this mechanism has 
become the target of new clinical trials involving 
CRPC (37). Inhibitors are being used to disrupt the 
three main components of the mechanism: PI3K, 
Akt, and mTOR. The inhibitors of PI3K and Akt are 
the most effective. However, these drugs are not 
effective in monotherapy and must be used together 
with other treatments, such as the PI3K/Akt-andro-
gen dual blockade (38). The use of antiandrogens 
in CRPC cases is senseless in principle; however, it 
has been noted that this resistance is reversible due 
to the activation of Akt (PKB). Therefore, the inhibi-
tion of the Akt pathway restores the responsiveness 
to androgens, predominantly in PTEN mutant cells 
fact. Nevertheless, the results of clinical trials vary 
due to the difference in the blockade produced by 
-
tiandrogens. These trials suggest that the optimal 
combination would be a PI3K or Akt inhibitor com-
bined with a new-generation antiandrogen, whose 
therapeutic effect could be improved with the use 
of metformin (40-42).
3.5. Effects of metformin on quiescent cancer stem 
cells
Amongst cancer cells resistant to ADT, there are 
cancer stem cells which remain in quiescent state 
by distinct markers which are listed in Table 2, can 
proliferate again at any time and cause a recurren-
ce of the cancer. There is evidence that metformin 
can selectively act in stem cells to inhibit the can-
cer proliferation and sensitize them to enhance the 
effects of other treatments (43, 44). It is important to 
highlight that the cells must express the membrane 
transporter OCT1 in order for metformin to correct-
-
ter allows the mitochondrial membrane potential 
to attract metformin into the mitochondria, thus 
reaching high concentrations. However, the expres-
sion of OCT1 in prostate cancer stem cells has not 
3.6. Discussion of the antineoplastic effects of 
metformin
A decrease in tumor proliferation was determined in 
vitro in mice, however, the doses used in this type of 
studies are between 100 and 300 times higher than 
those used in standard antidiabetic treatments (14).
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4. Conclusion
metformin in PCa, further research is needed to 
explain critical questions that remain unanswered. 
For example, it is still unclear whether the effects 
and tumors, whether the conventional antidiabe-
tic dose is the optimal anticancer dose, or whether 
metformin plays a role in the prevention or in the 
treatment of PCa, or in both. In addition, the poten-
tial side effects have not been studied thoroughly 
enough.
Metformin is an oral antidiabetic drug with an-
titumor effects in vitro. However, the true poten-
tial of metformin as an antineoplastic agent is yet 
to be established. There are numerous confounding 
factors in retrospective studies and there is a lack 
of research involving non-diabetics. This raises the 
question of whether it is actually the management 
of diabetes, and not metformin itself, that lowers 
the risk of developing cancer and increases the sur-
vival rate in cancer patients (particularly those un-
dergoing ADT). Yet again, further, more extensive 
studies are needed to assess the long-term effects of 
metformin.
metformin in PCa, especially when used in combi-
studies should follow critical and rigorous metho-
dology to determine if the effects of metformin can 
have real clinical impact.
-
terest in this article.
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Table 2:
